

VeriChip Corporation and RECEPTORS LLC to Develop Sensor Systems to Detect Biological Threats Such as Swine Flu and other Illnesses

Companies to publish whitepaper, "An Integrated Sensor System for the Detection of Bio-Threats from Pandemics to Emerging Diseases to Bio-Terrorism," available May 7, 2009, at www.verichipcorp.com

DELRAY BEACH, FL, and CHASKA, MN – May 6, 2009 – VeriChip Corporation (“VeriChip”) (NASDAQ: CHIP) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, today announced plans to develop surveillance and point-of-care sensor systems that will efficiently detect and identify the presence of a particular biological threat such as influenza virus, Methicillin-resistant Staphylococcus aureus (MRSA) or other illnesses. The companies will publish a white paper outlining the development of “An Integrated Sensor System for the Detection of Bio-Threats from Pandemics to Emerging Diseases to Bio-Terrorism,” which will be available May 7, 2009, on VeriChip’s website at www.verichipcorp.com.

The products currently in the marketplace to detect and identify such biological threats fail to provide a comprehensive solution for threat detection and, importantly, are not stable or scalable. Additionally, current testing methods are typically too specific to effectively screen for the broad range of potential agents. Current methods also may require specialized sample handling in a laboratory setting and take in excess of 24 hours to produce results. The companies’ products are expected to produce results on-site within 20 minutes against a broad range of potential biological threats in a method that is environmentally stable and economically scalable.

Robert E. Carlson, Ph.D., President and Chief Science Officer at RECEPTORS LLC, said, “Through our development partnership with VeriChip, we are focused on building an integrated suite of products that will identify a biological threat, from pandemic influenza and multiple-resistant pathogens like MRSA, to food borne illnesses such as salmonella and E. coli. The combination of our CARA platform and VeriChip’s signal transduction and communication capabilities provide both the technology and the expertise required to build the integrated bio-threat sensor system.”

Scott R. Silverman, Chairman of VeriChip, said, "As we continue to build on our partnership with RECEPTORS, which started with the development of a glucose-sensing RFID implantable microchip, we are moving beyond patient identification to sensors that can detect and identify illnesses and viruses such as influenza. This is an exciting next step for the future of our healthcare division.”

Last week, VeriChip announced it has expanded its existing development partnership with RECEPTORS, beyond the glucose-sensing RFID implantable microchip to include other biological and environmental applications. RECEPTORS recently received Patent No. 7,504,364 titled “Methods of Making Arrays and Artificial Receptors” and Patent No. 7,469,076 “Sensors Employing Combinatorial Artificial Receptors,” which are being applied to the development of diagnostic and sensor platforms for pathogens and other biological threats.

About RECEPTORS LLC

RECEPTORS LLC is a private company based in Chaska, Minnesota. RECEPTORS' mission is to advance the diagnosis and treatment of disease and to enhance the health, safety, and quality of

the global environment through the development and application of artificial receptor products for both research and industry. RECEPTORS' AFFINITY by DESIGN™ technology is the foundation of its SMART MATERIALS product platform. Each product incorporates RECEPTORS' core competence of surface functionalization for selective binding. This high-throughput approach to the development of stable, selective and scalable binding environments can be tailored to any product and application. For further information please visit <http://www.receptorsllc.com> or email info@receptorsllc.com.

About VeriChip

VeriChip Corporation, headquartered in Delray Beach, Florida, has developed the VeriMed™ Health Link System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, cleared for medical use in October 2004 by the United States Food and Drug Administration. To complement its healthcare division, VeriChip Corporation established VeriGreen Energy Corporation in March 2009 to focus and invest in the clean and alternative energy sector.

For more information on VeriChip, please call 1-800-970-2447, or e-mail info@verichipcorp.com. Additional information can be found online at www.verichipcorp.com.

Statements about VeriChip's future expectations, including its ability to develop and market a glucose-sensing microchip in conjunction with its development partner RECEPTORS LLC, its ability to expand its development partnership with RECEPTORS LLC to include other biological and environmental applications, and the ability of the biological and environmental applications that are to be jointly developed and marketed by it and RECEPTORS LLC to detect, among other things, influenza, swine flu MRSA, salmonella, E. coli, and other proteins, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and VeriChip's actual results could differ materially from expected results. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on February 12, 2009, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

###

Contact:
Allison Tomek
561-805-8000